- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02414633
Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI])
October 15, 2018 updated by: AbbVie
Special Investigation (Working Productivity and Activity Impairment in Japanese Patients With Psoriatic Arthritis)
A special investigation (post marketing observational study [PMOS]/non-mandatory) of HUMIRA® in Japanese psoriatic arthritis patients who are engaged in paid work.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
148
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
This is a single-arm, multi-center study with a prospective cohort.
Description
Inclusion Criteria:
- Paid workers (including part-time) with Psoriatic Arthritis, who have never administered adalimumab, and are diagnosed by ClASsification of Psoriatic ARthritis (CASPAR) criteria
Exclusion Criteria:
- Subjects showing decreased basic activities of daily life such as hospitalization and bedridden
- Subjects with contraindications to adalimumab
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Humira
Subjects with Psoriatic Arthritis taking adalimumab under conditions of daily clinical practice.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Work Productivity and Activity Impairment Psoriatic Arthritis Questionnaire (WPAI:PsA) Percentage of Overall Work Impairment (OWI): Change From Baseline to Week 24
Time Frame: Baseline (Week 0), Week 24
|
WPAI:PsA is a questionnaire used to evaluate lost productivity due to PsA; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.
Percentage of overall work impairment due to PsA (OWI) is calculated as: Absenteeism + (1 - Absenteeism) * Presenteeism.
Change from baseline was calculated as the value at baseline minus the value at each subsequent time point.
A negative change represents improvement.
|
Baseline (Week 0), Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
WPAI:PsA Percentage of OWI: Change From Baseline to Weeks 4, 12, and 16
Time Frame: Baseline (Week 0), Week 4, Week 12, and Week 16
|
WPAI:PsA is a questionnaire used to evaluate lost productivity due to PsA; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.
Percentage of overall work impairment due to PsA (OWI) is calculated as: Absenteeism + (1 - Absenteeism) * Presenteeism.
Change from baseline was calculated as the value at baseline minus the value at each subsequent time point.
A negative change represents improvement.
|
Baseline (Week 0), Week 4, Week 12, and Week 16
|
WPAI:PsA Absenteeism: Change From Baseline to Weeks 4, 12, 16 and 24
Time Frame: Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
WPAI:PsA is a questionnaire used to evaluate lost productivity due to PsA; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.
Absenteeism (percentage of work time missed due to PsA) is calculated as the number of hours of work missed due to PsA / (number of hours of work missed due to PsA + number of hours worked) * 100.
Change from baseline was calculated as the value at baseline minus the value at each subsequent time point.
A negative change represents improvement.
|
Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
WPAI:PsA Presenteeism: Change From Baseline to Weeks 4, 12, 16 and 24
Time Frame: Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
WPAI:PsA is a questionnaire used to evaluate lost productivity due to PsA; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.
Presenteeism (percentage of impairment while working due to PsA) is calculated as the patient's rating of how much PsA affected productivity while working (0 = no effect; 10 = completely prevented from working) / 10 * 100.
Change from baseline was calculated as the value at baseline minus the value at each subsequent time point.
A negative change represents improvement.
|
Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
WPAI:PsA Activity Impairment: Change From Baseline to Weeks 4, 12, 16 and 24
Time Frame: Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
WPAI:PsA is a questionnaire used to evaluate lost productivity due to PsA; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.
Activity impairment (percentage of activity impairment due to PsA) is calculated as the patient's rating of how much PsA affected their ability to do regular daily activities, other than working at a job (0 = no effect; 10 = completely prevented from working) / 10 * 100.
Change from baseline was calculated as the value at baseline minus the value at each subsequent time point.
A negative change represents improvement.
|
Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
Psoriatic Arthritis Screening and Evaluation Questionnaire (PASE): Change From Baseline to Weeks 4, 12, 16 and 24
Time Frame: Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
The PASE is a patient-administered questionnaire used to screen patients with psoriasis for evidence of psoriatic arthritis.
The PASE consists of 15 questions divided into 2 subscales (system sub-scale and function sub-scale); 7 questions assess symptoms and 8 questions assess function.
Questions are scored on a numeric scale ranging from 1 (strongly disagree) to 5 (strongly agree), with a total possible PASE score of 15 to 75.
Individuals who are more likely to have PsA will score higher than individuals without PsA.
Change from baseline was calculated as the value at baseline minus the value at each subsequent time point.
A negative change represents improvement.
|
Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
Psoriasis Area and Severity Index (PASI) Score: Change From Baseline to Weeks 4, 12, 16 and 24
Time Frame: Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on of the lesions rated on a a scale from 0 (no symptoms) to 4 (very marked), together with the percentage of the area affected, rated on a scale from 0 (0%) to 6 (100%).
PASI scoring is performed at four body areas, the head, arms, trunk, and legs.
The total PASI score ranges from 0 to 72.
The higher the total score, the more severe the disease.
Change from baseline was calculated as the value at baseline minus the value at each subsequent time point.
A negative change represents improvement.
|
Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
Disease Activity Score 28, C-reactive Protein (DAS28 [CRP]): Change From Baseline to Weeks 4, 12, 16 and 24
Time Frame: Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
DAS28 (CRP) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein (CRP) level, and the patient's global assessment of disease activity via the visual analog scale (VAS).
The calculated range of DAS28-4 is 0 to 10.
A score less than 2.6 indicates clinical remission, a score of 2.6 to 3.2 indicates low disease activity, a score of 3.2 to less than 5.1 indicates moderate disease activity, and a score of 5.1 or greater indicates high disease activity.
Change from baseline was calculated as the value at baseline minus the value at each subsequent time point.
A negative change represents improvement.
|
Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
Disease Activity Score 28, Erythrocyte Sedimentation Rate (DAS28 [ESR]): Change From Baseline to Weeks 4, 12, 16 and 24
Time Frame: Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
DAS28 (ESR) is calculated using the number of tender and swollen joints (out of 28 counted), erythrocyte sedimentation rate (ESR), and the patient's global assessment of disease activity via the visual analog scale (VAS).
The calculated range of DAS28-4 is 0 to 10.
A score less than 2.6 indicates clinical remission, a score of 2.6 to 3.2 indicates low disease activity, a score of 3.2 to less than 5.1 indicates moderate disease activity, and a score of 5.1 or greater indicates high disease activity.
Change from baseline was calculated as the value at baseline minus the value at each subsequent time point.
A negative change represents improvement.
|
Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
Tender Joint Count (TJC68): Change From Baseline to Weeks 4, 12, 16 and 24
Time Frame: Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
At each study visit, a joint evaluator assessed whether a particular joint was "tender or painful" where presence of tenderness was scored as "1" and the absence of tenderness was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons.
The total TJC68, which is based on 68 joints, was derived as the sum of all "1s" thus collected with no penalty considered for the joints not assessed or those which had been replaced.
The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness.
Change from baseline was calculated as the value at baseline minus the value at each subsequent time point.
A negative change represents improvement.
|
Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
Swollen Joint Count (SJC66): Change From Baseline to Weeks 4, 12, 16 and 24
Time Frame: Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as "1" and the absence of swelling was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons.
The total SJC66, which is based on 66 joints, was derived as the sum of all "1s" thus collected with no penalty considered for the joints not assessed or those which had been replaced.
The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling.
Change from baseline was calculated as the value at baseline minus the value at each subsequent time point.
A negative change represents improvement.
|
Baseline (Week 0), Week 4, Week 12, Week 16, and 24
|
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Change From Baseline to Weeks 12 and 24
Time Frame: Baseline (Week 0), Week 12, and Week 24
|
The BASDAI uses a scale from 1 (no problem) to 10 (worst problem) to answer 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain/swelling, areas of localized tenderness (also called enthesitis, or inflammation of tendons and ligaments), morning stiffness duration, and morning stiffness severity.
To give each symptom equal weighting, the mean (average) of the two scores relating to morning stiffness is taken.
The resulting 0 to 50 score is divided by 5 to give a final BASDAI score ranging from 0-10.
Change from baseline was calculated as the value at baseline minus the value at each subsequent time point.
A negative change represents improvement.
|
Baseline (Week 0), Week 12, and Week 24
|
Health Assessment Questionnaire Disability Index (HAQ-DI): Change From Baseline to Weeks 12 and 24
Time Frame: Baseline (Week 0), Week 12, and Week 24
|
The HAQ-DI is a patient-reported outcome which is usually self-administered by the patient.
The HAQ-DI assesses the categories of dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities.
The patients report the amount of difficulty they have in performing these activities using a scale ranging from 0 (can be performed without any difficulty) to 3 (cannot be done at all).
Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability.
Change from baseline was calculated as the value at baseline minus the value at each subsequent time point.
A negative change represents improvement.
|
Baseline (Week 0), Week 12, and Week 24
|
Enthesitis: Change From Baseline to Final Visit
Time Frame: Baseline (Week 0) and final visit (up to 24 weeks)
|
The percentage of participants with enthesitis.
|
Baseline (Week 0) and final visit (up to 24 weeks)
|
Dactylitis: Change From Baseline to Final Visit
Time Frame: Baseline (Week 0) and final visit (up to 24 weeks)
|
The percentage of participants with dactylitis.
|
Baseline (Week 0) and final visit (up to 24 weeks)
|
Spondylitis: Change From Baseline to Final Visit
Time Frame: Baseline (Week 0) and final visit (up to 24 weeks)
|
The percentage of participants with spondylitis.
|
Baseline (Week 0) and final visit (up to 24 weeks)
|
Nail Psoriasis: Change From Baseline to Final Visit
Time Frame: Baseline (Week 0) and final visit (up to 24 weeks)
|
The percentage of participants with nail psoriasis .
|
Baseline (Week 0) and final visit (up to 24 weeks)
|
Number of Participants With Adverse Events (AEs)
Time Frame: From the first dose of study drug until the end of the study (up to 24 weeks)
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
The investigator assessed the relationship of each event to the use of study drug as either probable, possible, not related, or impossible to judge.
A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above.
Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the physician obtained the patient's authorization or informed consent until the end of the study (week 28 or discontinuation).
|
From the first dose of study drug until the end of the study (up to 24 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Sarina Kurimoto, MD, AbbVie GK.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2015
Primary Completion (Actual)
March 13, 2017
Study Completion (Actual)
March 13, 2017
Study Registration Dates
First Submitted
January 30, 2015
First Submitted That Met QC Criteria
April 8, 2015
First Posted (Estimate)
April 13, 2015
Study Record Updates
Last Update Posted (Actual)
October 16, 2018
Last Update Submitted That Met QC Criteria
October 15, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P15-084
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriatic Arthritis
-
AmgenRecruitingActive Juvenile Psoriatic ArthritisSpain, United Kingdom, Turkey, Belgium, France, Greece, Italy, Austria, Germany, Netherlands, Poland, Portugal, Romania, Lithuania, South Africa
-
Universitätsklinikum Hamburg-EppendorfBristol-Myers Squibb; Eli Lilly and Company; UCB Pharma; Merck Sharp & Dohme LLC; AbbVi... and other collaboratorsRecruiting
-
Bristol-Myers SquibbCompletedPsoriatic Arthritis (PsA)Germany
-
Pope Research CorporationAmgenWithdrawn
-
Sun Pharmaceutical Industries LimitedRecruitingActive Psoriatic ArthritisUnited States, Australia, Czechia, Estonia, Korea, Republic of, Poland, Slovakia, Spain, Taiwan, Germany, Italy, India, Canada
-
Humanis Saglık Anonim SirketiCompletedPsoriasis and Psoriatic ArthritisIndia
-
Novartis PharmaceuticalsCompletedPlaque Psoriasis, Psoriatic ArthritisSwitzerland
-
Sun Pharmaceutical Industries LimitedActive, not recruitingActive Psoriatic ArthritisUnited States, Australia, Czechia, Germany, India, Japan, Korea, Republic of, Poland, Spain
-
AbbVieActive, not recruitingPsoriatic Arthritis (PsA)United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
-
Sun Pharmaceutical Industries LimitedCompleted